Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has provided an announcement.
Medicenna Therapeutics Corp announced that updated clinical data from their Phase 1/2 ABILITY-1 Study on MDNA11 will be presented at the European Society for Medical Oncology Immuno-Oncology Congress 2025. This presentation will highlight the potential of MDNA11 as a monotherapy and in combination with pembrolizumab for treating advanced solid tumors, potentially enhancing Medicenna’s position in the immunotherapy market and offering new hope for stakeholders in cancer treatment.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company that specializes in developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, as well as first-in-class Empowered Superkines. Their focus is on creating advanced therapies for cancer and autoimmune diseases, with products like MDNA11, a next-generation IL-2 Superkine, and MDNA113, a targeted PD-1 x IL-2 bispecific for solid tumors.
Average Trading Volume: 38,422
Technical Sentiment Signal: Sell
Current Market Cap: C$64.6M
Find detailed analytics on MDNA stock on TipRanks’ Stock Analysis page.